RxDoctor Payments DataLook up a doctor →

Boris Leybel, MD

Pain Medicine · New York, NYNPI 1578508685

Payments from drug & device makers

$58,252in general payments, 2019–2025

Across 1,126 payments — averaging $51.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$25K
  • Biohaven Pharmaceuticals, Inc.$13K
  • Biohaven Pharmaceutical Holding Company Ltd.$8K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Scilex Pharmaceuticals Inc.$2K
  • Amgen$1K
  • plus $8K from 37 others

What the payments were for

  • Speaking & faculty fees$40,30069%
  • Food & beverage$17,87331%
  • Education$780%
  • Gifts$00%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,252 in reported general payments places this provider in the 95th percentile of 503 pain medicine providers in New York.

See all pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$482,709
Medicare patients
244
Services billed
37,513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate77$130,318
AustedoDeutetrabenazine16$103,968
Austedo XrDeutetrabenazine12$89,495
ZtlidoLidocaine80$43,665
NamzaricMemantine Hcl/Donepezil Hcl75$42,035
Diclofenac Sodium57$25,408
NourianzIstradefylline11$22,935
TrintellixVortioxetine Hydrobromide50$22,722
NuedextaDextromethorphan Hbr/Quinidine15$22,273
RytaryCarbidopa/Levodopa28$21,169
QuliptaAtogepant21$20,743
Doxepin Hcl85$19,623
Ajovy AutoinjectorFremanezumab-Vfrm21$16,063
OngentysOpicapone15$9,929
Ajovy SyringeFremanezumab-Vfrm12$8,654

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$2,236$193,46328 claims
PfizerNurtec Odt$1,100$130,31877 claims
AbbVieNamzaric, Qulipta$24,715$62,77996 claims
Scilex Pharmaceuticals Inc.Ztlido$1,660$43,66580 claims
Kyowa Kirin, Inc.Nourianz$251$22,93511 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$313$22,72250 claims
Avanir Pharmaceuticals, Inc.Nuedexta$263$22,27315 claims
Amneal Pharmaceuticals LLCRytary$333$21,16928 claims
Neurocrine Biosciences, Inc.Ongentys$518$9,92915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 503 pain medicine providers in New York.

Other pain medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →